Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer

Rhea-AI Summary

Neurocrine Biosciences (NBIX) has appointed Lewis Choi as Chief Information Officer, effective June 9, 2025. Choi brings 25 years of experience in information technology and artificial intelligence, joining at a crucial time as the company focuses on launching CRENESSITY, growing INGREZZA, and advancing its pipeline. Previously, Choi spent 13 years at Thermo Fisher Scientific, most recently as VP of AI Automation & Data, where he held various leadership positions in digital platforms and solutions. His prior experience includes IT roles at Life Technologies, SysGroup Inc., Serene Corporation, ADP, and Corio, Inc. The appointment aligns with Neurocrine's strategic focus on leveraging technology to enhance business operations and treatment delivery.

Positive

• Appointment of experienced CIO with 25 years of technology and AI expertise
• Strong background in healthcare technology and digital transformation from Thermo Fisher Scientific
• Strategic timing coincides with company growth phase including CRENESSITY launch and INGREZZA expansion

Negative

• None.

News Market Reaction – NBIX

-0.76%

1 alert

-0.76% News Effect

On the day this news was published, NBIX declined 0.76%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, June 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Lewis Choi as Chief Information Officer, effective June 9, 2025. Choi, an accomplished leader with 25 years of experience in information technology and artificial intelligence, will be responsible for driving the vision and long-term strategic direction of the company's technology initiatives.

"Lewis is a proven global healthcare leader with a track record of utilizing technology to drive both cultural and technological change," said Matt Abernethy, Chief Financial Officer, Neurocrine Biosciences. "As we launch CRENESSITY, grow INGREZZA, and advance our pipeline, he joins Neurocrine at an exciting time when advancements in technology will play a critical role in advancing our mission to help more patients."

"I am excited to join Neurocrine at such a pivotal time for the company," Choi said. "I look forward to leveraging innovative IT and digital solutions to strengthen the business and support the teams who work tirelessly to discover, develop and deliver critical treatments for patients."

Choi joins Neurocrine after a 13-year career at Thermo Fisher Scientific, most recently as the Vice President of AI Automation & Data. Previously, he was Global Vice President of Digital Platforms, Engineering & Generative AI; Vice President of Digital Solutions for APAC and Emerging Markets; and Vice President of Corporate Solutions & Integrations. Prior to that, he held IT roles at Life Technologies (prior to its acquisition by Thermo Fisher Scientific), SysGroup Inc., Serene Corporation, ADP, and Corio, Inc. and earned a Bachelor of Arts degree at the University of California, Berkeley.

About Neurocrine Biosciences

Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, and Facebook. (*in collaboration with AbbVie)

NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, YOU DESERVE BRAVE SCIENCE, INGREZZA, and CRENESSITY are registered trademarks of Neurocrine Biosciences, Inc. 

 © 2025 Neurocrine Biosciences, Inc. All Rights Reserved. 06/2025 

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-appoints-lewis-choi-as-chief-information-officer-302476717.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

Who is the new CIO of Neurocrine Biosciences (NBIX)?

Lewis Choi has been appointed as the new Chief Information Officer of Neurocrine Biosciences, effective June 9, 2025.

What is Lewis Choi's previous work experience before joining NBIX?

Choi spent 13 years at Thermo Fisher Scientific, most recently as VP of AI Automation & Data, and previously held IT roles at Life Technologies, SysGroup Inc., Serene Corporation, ADP, and Corio, Inc.

What will be Lewis Choi's main responsibilities at Neurocrine Biosciences?

Choi will be responsible for driving the vision and long-term strategic direction of the company's technology initiatives, focusing on innovative IT and digital solutions to strengthen the business.

Why did Neurocrine Biosciences appoint a new CIO at this time?

The appointment comes at a strategic time as the company focuses on launching CRENESSITY, growing INGREZZA, and advancing its pipeline, where technology advancements will play a critical role in their mission.